EQ BOKU’s high-tech equipment at the University of Natural Resources and Life Sciences, Vienna enables precise analysis of factors influencing the storability of natural colouring concentrates. Vienna, 31 July 2019 – The shelf life of vegetable carotenoids when stored in…
Keep Your Diet Healthy and Diverse with Recipe Calendar 2.0
Recipe Calendar is a meal planner that offers 50+ diet plans and automatically generates a shopping list for the chosen recipes. Virtually anyone can find a suitable menu: vegetarian, paleo, low carb, mom and child, gluten-free, etc. The new version…
EU Healthcare Systems: a Reallocation Of Resources Is Urgently Needed
Turning away from “low-value†(waste, overuse) towards “high-value†health care is critical for the sustainability of solidarity-based healthcare systems. The Ludwig Boltzmann Institute for Health Technology Assessment is represented on the European Expert Panel. Vienna, 11. July 2019 – On…
Mobius Book Review: “The Liebold Protocol: A Mattie McGary and Winston Churchill 1930s Adventure” Written by Michael McMenamin and Kathleen McMenamin
“Fast-paced historical thriller with a strong female lead.” Reviewed by Kirsten from Mobius. Shaker Heights, OH, USA — In another stunning Mattie McGary and Winston Churchill 1930s adventure novel, The Liebold Protocol, the McMenamins follow Mattie as she investigates and…
An extensive portfolio revealed at the Learning Technologies Summer Forum
Over 100 e-learning courses on Health and Safety, Compliance, Leadership and Management, IT and Project Management, Business Skills and Customer Services will be on show on the Engage in Learning stand at this year’s Learning Technologies Summer Forum, being held…
Investors Support Phage Therapy: Novel Approach to Solve the Antibiotics Crisis Receives Further Millions
Vienna (Austria), 27 June 2019: Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further EUR 1.5…